Prostate cancer research has been greatly hindered by the paucity of new investigators entering into the field. In recognition of the need to help establish independently funded investigators in the field of translational prostate cancer research, the UM Prostate SPORE has supported two to three junior faculty per year. The focus of the Career Development Program (CDP) is to provide investigators the resources to generate preliminary data for subsequent NIH ROI grant applications. The UM Prostate SPORE commits $70,000 annually per investigator. Career Development awardees are funded for a maximum of two years, subject to annual review. The awardees'departments supply another $10,000 per year in matching funds. Investigators, many of whom are outside the field of prostate cancer, meet quarterly with Drs. Cooney and Robins who act as clinical resource and basic science mentors, respectively. A former CDP investigator. Dr. Cooney is a medical oncologist with appointments in internal medicine and urology. Dr. Cooney is the

Public Health Relevance

The UM Prostate SPORE continues to emphasize the importance of the CDP as an integral part of the of our prostate cancer research community. Through a process of rigorous peer review, we continue to encourage innovative and high risk / high reward prostate cancer research by new investigators to the field while providing them a supportive mentoring environment. Our ultimate goal is to decrease the morbidity and mortality of prostate cancer through innovative research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA186786-01
Application #
8788158
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
2014-09-11
Project End
2019-08-31
Budget Start
2014-09-11
Budget End
2015-08-31
Support Year
1
Fiscal Year
2014
Total Cost
$94,671
Indirect Cost
$33,630
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Zhang, Yajia; Pitchiaya, Sethuramasundaram; Cie?lik, Marcin et al. (2018) Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression. Nat Genet 50:814-824
Hussain, Maha; Daignault-Newton, Stephanie; Twardowski, Przemyslaw W et al. (2018) Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol 36:991-999
Salami, Simpa S; Hovelson, Daniel H; Kaplan, Jeremy B et al. (2018) Transcriptomic heterogeneity in multifocal prostate cancer. JCI Insight 3:
Zhao, Shanshan; Leonardson, Amy; Geybels, Milan S et al. (2018) A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancer. Prostate :
Niknafs, Yashar S; Pandian, Balaji; Gajjar, Tilak et al. (2018) MiPanda: A Resource for Analyzing and Visualizing Next-Generation Sequencing Transcriptomics Data. Neoplasia 20:1144-1149
Xiao, Lanbo; Tien, Jean C; Vo, Josh et al. (2018) Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer. Cancer Res 78:5731-5740
Piert, Morand; Shankar, Prasad R; Montgomery, Jeffrey et al. (2018) Accuracy of tumor segmentation from multi-parametric prostate MRI and 18F-choline PET/CT for focal prostate cancer therapy applications. EJNMMI Res 8:23
Wu, Yi-Mi; Cie?lik, Marcin; Lonigro, Robert J et al. (2018) Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer. Cell 173:1770-1782.e14
Robinson, Dan R; Wu, Yi-Mi; Lonigro, Robert J et al. (2017) Integrative clinical genomics of metastatic cancer. Nature 548:297-303
Jin, Feng; Thaiparambil, Jose; Donepudi, Sri Ramya et al. (2017) Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer. Cancer Prev Res (Phila) 10:588-597

Showing the most recent 10 out of 65 publications